This review aims to clarify the complex and nuanced role of mitochondrial ROS in aging by focusing on ROS production within mitochondria, especially complexes I, II and III, and exploring how these localized ROS influence various hallmarks of aging to contribute to the aging phenotype.
Abstract
Aging is characterized by a progressive decline in cellular integrity and function, making it a major risk factor for numerous disease pathologies. Mitochondrial dysfunction and oxidative stress have long been recognized as contributors to the aging phenotype. The loss of mitochondrial function and the overproduction of reactive oxygen species (ROS) are linked to many hallmarks of aging and are associated with a wide range of diseases; however, their role in the aging process is nuanced. Mitochondria produce ROS as harmful respiratory byproducts, but ROS can also act as a signaling molecule with emerging functions linked to variables such as location, timing, and quantity. Similarly, mitochondrial dysfunction is often broadly categorized, overlooking its multifaceted nature and diverse contributions to aging. Due to this complexity, our understanding of how mitochondrial ROS production shapes disease processes and aging hallmarks remains limited. This review aims to clarify the complex and nuanced role of mitochondrial ROS in aging by focusing on ROS production within mitochondria, especially complexes I, II and III, and exploring how these localized ROS influence various hallmarks of aging to contribute to the aging phenotype.
More research in the field may unravel the mechanistic details of the organellar crosstalk that works in concert with classical aging pathways to sustain aging progression, which may help promote healthier aging.
Recent studies demonstrate promising therapeutic targets for mitochondrial dysfunction and highlight the need for research in mitochondrial function to change the therapeutic landscape in the management of mitochondrial dysfunction-associated diseases.
Olufemi Akintayo Akinkunmi, Feyikemi Funmilayo Araba, J. A. Chukwudebelu et al.· Frontiers in Cell and Develo...· 0 citations
This review integrates current understanding of mitochondrial permeability transition with emerging evidence implicating three novel regulatory components: F-ATP synthase inhibitory factor 1 (IF1), subunit j of F-ATP synthase, and mitochondrial carrier homolog 2 (MTCH2), expanding the therapeutic landscape for treating...
Lishu Guo· Journal of Molecular Neurosc...· 0 citations
The molecular assembly, physiological roles, and longevity implications of SC in healthy mammals, and emerging evidence supporting SC modulation as a potential strategy for promoting healthy aging are discussed.
Shinichiro Suzuki, K. Ikeda, Toshihiko Takeiwa et al.· Frontiers in Aging· 0 citations
It is demonstrated that mitochondrial impairment precedes classical neuropathological hallmarks, thereby positioning mitochondrial dysfunction as a primary driver rather than a secondary consequence of neurodegeneration, and critically evaluates the translational landscape of mitochondria-targeted interventions.
Zhaomin Yao, Yang-Wa Wei, Weiming Xie et al.· Ageing Research Reviews· 0 citations
Overall, aging outcomes reflect a dynamic equilibrium between damage and repair processes, and how this balance is modulated in long-lived individuals may inform strategies to promote healthy aging and delay the onset of age-related diseases.
S. Sideri, M. Cosentino, Laura Forcina et al.· Mechanisms of Ageing and Dev...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.